For Investors

Corporate Profile
AVEO Oncology is a biopharmaceutical company committed to discovering and developing targeted therapies designed to provide substantial impact in the lives of people with cancer by addressing unmet medical needs. AVEO’s proprietary Human Response Platform provides the company unique insights into cancer and related disease biology and is being leveraged in the discovery and clinical development of its therapeutic candidates.
Stock Quote
AVEO (Common Stock)
ExchangeNASDAQ (US Dollar)
Change (%) Stock is Down 0.05 (3.60%)
Data as of 04/17/14 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent Press Releases 
04/10/14AVEO and Biodesix Partner to Co-Develop and Commercialize Ficlatuzumab with a Companion Diagnostic for Treatment of NSCLC
Biodesix to Fund Proof of Concept Study CAMBRIDGE, Mass. & BOULDER, Colo.--(BUSINESS WIRE)--Apr. 10, 2014-- AVEO Oncology (NASDAQ: AVEO) and Biodesix, Inc. today announced that they have entered into a worldwide agreement to develop and commercialize AVEO’s hepatocyte growth factor (HGF) inhibitory antibody ficlatuzumab, with a Biodesix® companion diagnostic test. This agreement and the clinical development program will leverage VeriStrat®... 
Printer Friendly Version
03/20/14AVEO Regains Worldwide Rights to AV-203
Agreement with Biogen Idec allows AVEO to seek partner to accelerate clinical development CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 20, 2014-- AVEO Oncology (NASDAQ: AVEO) today announced that it has regained worldwide rights to AV-203, a clinical-stage ErbB3 (HER3) inhibitory antibody candidate, from Biogen Idec. “We are pleased to regain rights for AV-203 as we believe in the potential of this innovative therapy and are looking forward... 
Printer Friendly Version
03/13/14AVEO Oncology Reports Full Year 2013 Financial Results and Outlines 2014 Strategic Plan
- Company ends 2013 with $118M in cash1 - - Focuses internal R&D investment on AV-380 in cachexia - - Intends to advance clinical-stage assets through strategic partnering – CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 13, 2014-- AVEO Oncology (NASDAQ: AVEO) today reported consolidated 2013 financial results and outlined its 2014 strategic plan and financial guidance. “With the cost-containment measures implemented in th... 
Printer Friendly Version
More Press Releases >>
Upcoming Events 
There are currently no events scheduled.
More Events >>
7th Annual Cachexia Conference, GDF-15 oral presentation
AACR 2013, Cancer Cachexia poster - Abstract 4650, Vigano
AACR 2013, GDF-15 poster - Abstract 3504, Lerner
ASCO GU 2013 Tivozanib TIVO-1 Hypoxia Signature ccRCC - Abstract 361, Robinson
ASCO GU 2013 Tivozanib TIVO-1 Overall Survival - Abstract 350, Motzer
More Presentations >>

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.